Depo-Eligard 45 mg inj. sol. (pwdr. + solv.) s.c. pre-filled syr. Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

depo-eligard 45 mg inj. sol. (pwdr. + solv.) s.c. pre-filled syr.

recordati industria chimica e farmaceutica s.p.a. - leuprorelin acetate 45 mg - eq. leuprorelin 41,7 mg - powder and solvent for solution for injection - 45 mg - leuprorelin acetate 45 mg - leuprorelin

ELIGARD 22.5 mg powder and solvent for solution for injection Ireland - English - HPRA (Health Products Regulatory Authority)

eligard 22.5 mg powder and solvent for solution for injection

recordati industria chimica e farmaceutica spa - leuprorelin acetate - powder and solvent for solution for injection - 22.5 milligram(s) - gonadotropin releasing hormone analogues; leuprorelin

ELIGARD 45 mg powder and solvent for solution for injection Ireland - English - HPRA (Health Products Regulatory Authority)

eligard 45 mg powder and solvent for solution for injection

recordati industria chimica e farmaceutica spa - leuprorelin acetate - powder and solvent for solution for injection - 45 milligram(s) - gonadotropin releasing hormone analogues; leuprorelin

ELIGARD 7.5 mg powder and solvent for solution for injection Ireland - English - HPRA (Health Products Regulatory Authority)

eligard 7.5 mg powder and solvent for solution for injection

recordati industria chimica e farmaceutica spa - leuprorelin acetate - powder and solvent for solution for injection - 7.5 milligram(s) - gonadotropin releasing hormone analogues; leuprorelin

LERIN leuprorelin (as acetate) 5 mg implant pre-filled syringe Australia - English - Department of Health (Therapeutic Goods Administration)

lerin leuprorelin (as acetate) 5 mg implant pre-filled syringe

sandoz pty ltd - leuprorelin acetate, quantity: 5.25 mg (equivalent: leuprorelin, qty 5 mg) - implant - excipient ingredients: polylactic acid - palliative treatment of patients with advanced prostate carcinoma.

LERIN leuprorelin (as acetate) 3.6 mg implant pre-filled syringe Australia - English - Department of Health (Therapeutic Goods Administration)

lerin leuprorelin (as acetate) 3.6 mg implant pre-filled syringe

sandoz pty ltd - leuprorelin acetate, quantity: 3.78 mg (equivalent: leuprorelin, qty 3.67 mg) - implant - excipient ingredients: polyglactin - palliative treatment of patients with advanced prostate carcinoma.

LUCRIN PDS DEPOT 11.25 MG Israel - English - Ministry of Health

lucrin pds depot 11.25 mg

abbvie biopharmaceuticals ltd, israel - leuprorelin acetate - powder and solvent for suspension for injection - leuprorelin acetate 11.25 mg - leuprorelin - endometriosis, prostatic cancer, treatment of uterine fibroids for a period of up to six months. treatment of breast cancer in pre- and peri - menopausal women in whom hormone therapy is specified.

LUCRIN PDS DEPOT 11.25 MG Israel - English - Ministry of Health

lucrin pds depot 11.25 mg

abbvie biopharmaceuticals ltd, israel - leuprorelin acetate - powder and solvent for suspension for injection - leuprorelin acetate 11.25 mg - leuprorelin - endometriosis, prostatic cancer, treatment of uterine fibroids for a period of up to six months. treatment of breast cancer in pre- and peri - menopausal women in whom hormone therapy is specified.

LUCRIN PDS DEPOT 3.75 MG Israel - English - Ministry of Health

lucrin pds depot 3.75 mg

abbvie biopharmaceuticals ltd, israel - leuprorelin acetate - powder and solvent for suspension for injection - leuprorelin acetate 3.75 mg - leuprorelin - endometriosis prostatic cancer treatment of uterine fibroids for a period of up to six months. treatment of breast cancer in pre- and peri - menopausal women in whom hormone therapy is specified.

LUCRIN PDS DEPOT 3.75 MG Israel - English - Ministry of Health

lucrin pds depot 3.75 mg

abbvie biopharmaceuticals ltd, israel - leuprorelin acetate - powder and solvent for suspension for injection - leuprorelin acetate 3.75 mg - leuprorelin - endometriosis prostatic cancer treatment of uterine fibroids for a period of up to six months. treatment of breast cancer in pre- and peri - menopausal women in whom hormone therapy is specified.